Skip to content

Minocycline Attenuate Postoperative Cognitive Dysfunction and Delirium

Minocycline Attenuate Postoperative Cognitive Dysfunction and Delirium: A Multicenter, Randomized, Double-Blind Clinical Trail

Status
UNKNOWN
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02928692
Acronym
MAPOCD
Enrollment
750
Registered
2016-10-10
Start date
2016-11-30
Completion date
2021-12-31
Last updated
2020-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Carcinoma of the Rectum, Colon Cancer, Prostate Cancer, Renal Carcinoma

Keywords

Minocycline, Postoperative cognitive dysfunction, Postoperative delirium

Brief summary

Postoperative cognitive dysfunction (POCD) and postoperative delirium occurs mainly in aged patients. POCD and POD may increase the mortality and morbidity. However, the mechanism of POCD is not clear yet and no effective therapy method was proved. According to previous study, the neuroinflammation is the main reason both for POCD and POD. Minocycline is a tetracycline derivative. Due to it's lipophilic structure, it is easy to pass through blood brain barrier and attenuate neuroinflammation. It's neuroprotective effects has been proven in many experimental animal models such as Alzheimer's disease, Huntington's disease and Parkinson's syndrome. In present study, the investigators hypothesized that minocycline would attenuate the incidence of POCD and POD in the aged patients.

Interventions

DRUGMinocycline
DRUGPlacebo

Sponsors

Shanghai 10th People's Hospital
CollaboratorOTHER
Pudong New Area People's Hospital
CollaboratorUNKNOWN
Shanghai Pudong Hospital
CollaboratorOTHER
Shanghai Pudong New Aera Dongming Community Health Care Center
CollaboratorUNKNOWN
RenJi Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

For the placebo and minocycline group; Inclusion Criteria: 1. Elder than 65 years old 2. Speak Chinese Mandarin 3. Those who will undergo major general surgery like colorectal cancer excision, major urinary surgery like radical prostatectomy and radical nephrectomy 4. Signed the inform consent 5. American Society of Anesthesiologists classification I to III

Exclusion criteria

1. Existing cerebral disease, or have a history of neurological and psychiatric diseases including Alzheimer Disease, stroke, epilepsy and psychosis; 2. Existing cognitive impairment as evidenced by Mini-Mental State Examination scores below 24; 3. Severe audition or vision disorder; 4. Unwillingness to comply with the protocol or procedures. 5. Cannot communicated with Chinese Mandarin 6. With severe skin disease 7. Serious heart or liver or renal insufficiency patients 8. Had surgery in the past 30 days 9. Allergy to tetracycline or minocycline For the health volunteers; Inclusion Criteria: 1. Elder than 65 years old 2. Speak Chinese Mandarin 3. Signed the inform consent 4. No major disease health people

Design outcomes

Primary

MeasureTime frame
POCD incidence 7 days (or before leaving hospital) after surgery7 days (or before leaving hospital)
POD incidence1 to 5 days after surgery

Secondary

MeasureTime frame
POCD incidence 2 months after surgery2 months after surgery

Countries

China

Contacts

Primary ContactDiansan Su, Doctor
diansansu@yahoo.com18616514088
Backup ContactHui Li, Master Degree Candidate
56428923@qq.com15216711923

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026